While the pathogenesis of drug-induced lupus erythematosus (DILE) is not completely understood, genetic, epigenetic, and environmental influences a......READ MORE
expert roundtables by Bevra H. Hahn, MD; Joan T. Merrill, MD; and George C. Tsokos, MD
Treat-to-target strategies in systemic lupus erythematosus (SLE) involve setting the treatment target to complete remission or to low disease activ......READ MORE
expert roundtables by Bevra H. Hahn, MD; Joan T. Merrill, MD; and George C. Tsokos, MD
Treatment goals in systemic lupus erythematosus (SLE) include achieving long-term patient survival, preventing flares and organ damage, and safegua......READ MORE
Low-dose interleukin-2 (IL-2) therapy continues to be studied as a potential approach for systemic lupus erythematosus (SLE), where it may restore ......READ MORE
Many patients with systemic lupus erythematosus (SLE) have high levels of type I interferon (IFN)–regulated genes in peripheral blood, known as the......READ MORE
expert roundtables by Bevra H. Hahn, MD; Joan T. Merrill, MD; and George C. Tsokos, MD
There have been 2 recent additions to the therapeutic landscape in systemic lupus erythematosus (SLE), with voclosporin and belimumab both showing ......READ MORE